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Abstract
Objectives—Annually, millions of people in sub-Saharan Africa (SSA) receive HIV counselling 
and testing (HCT), a service designed to inform persons of their HIV status and, if HIV-
uninfected, reduce HIV acquisition risk. However, the impact of HCT on HIV acquisition has not 
been systematically evaluated. We conducted a systematic review to assess this relationship in 
SSA.
Methods—We searched for articles from sub-Saharan Africa meeting the following criteria: an 
HIV-uninfected population, HCT as an exposure, longitudinal design, and an HIV acquisition 
endpoint. Three sets of comparisons were assessed and divided into strata: A) sites receiving HCT 
versus sites not receiving HCT, B) persons receiving HCT versus persons not receiving HCT, and 
C) persons receiving couple HCT versus persons receiving individual HCT.
Results—We reviewed 1635 abstracts; eight met all inclusion criteria. Strata A consisted of one 
cluster randomised trial with a non-significant trend towards HCT being harmful: incidence rate 
ratio (IRR): 1.4. Strata B consisted of five observational studies with non-significant unadjusted 
IRRs from 0.6 to 1.5. Strata C consisted of two studies. Both displayed trends towards couple 
HCT being more protective than individual HCT (IRRs: 0.3 to 0.5). All studies had at least one 
design limitation.
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Conclusions—In spite of intensive scale-up of HCT in SSA, few well-designed studies have 
assessed the prevention impacts of HCT. The limited body of evidence suggests that individual 
HCT does not have a consistent impact on HIV acquisition, and couple HCT is more protective 
than individual HCT.
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Introduction
In sub-Saharan Africa, the HIV response has intensified dramatically since 2003, when the 
President’s Emergency Plan for AIDS Relief (PEPFAR) was introduced. HIV counselling 
and testing (HCT), a gateway for HIV treatment, has been brought to scale with tens of 
millions of annual tests [1–4]. Individual and couple HCT are essential for linking HIV-
infected persons to HIV treatment, which reduces morbidity, mortality, and horizontal and 
vertical transmissibility [5, 6]. Similarly, individual and couple HCT can now serve as 
referral points for HIV-uninfected men to access medical male circumcision, and, in the near 
future, may serve as an entry-point for antiretroviral pre-exposure prophylaxis [7–9]. 
However, historically, individual and couple HCT relied strictly on behavioural HIV 
prevention messages. The relationship between individual and couple HCT and HIV 
acquisition is not well understood, in spite of three decades of implementation. Given the 
high volume of HCT, the high proportion of negative test results, and the slow scale-up of 
biomedical prevention, understanding the impact of individual and couple HCT on HIV 
acquisition is essential for guiding the magnitude and nature of future HCT rollout, as well 
as the relative emphasis of individual and couple HCT.
HCT typically consists of three components: pre-test counselling, HIV testing, and post-test 
counselling [10]. Typically, in pre-test counselling, HIV natural history and modes of 
transmission are explained, as well as behavioural HIV prevention measures. In individual 
pre-test-counselling, the counselling is tailored to the client’s personal risk factors. 
Currently, HIV testing is conducted with rapid tests with real-time results, but historically 
HIV testing was laboratory-based, with results becoming available days or weeks later. Post-
test counselling typically involves return of results with differentiated messages for HIV-
infected and HIV-uninfected clients. For HIV-infected clients, the discussion is focused on 
care and treatment, psychosocial support, and methods for preventing onward HIV 
transmission. For HIV-uninfected clients, messages address HIV acquisition through partner 
reduction, condom use, and faithfulness to one partner.
Couple HCT is an approach in which two members of a couple undergo HCT together, 
enabling both persons to learn their own status and their partner’s HIV status 
simultaneously. Couple HCT allows for a couple diagnosis: both persons HIV-uninfected 
(HIV concordant negative), both persons HIV-infected (HIV concordant positive), or one 
HIV-infected and the other HIV-uninfected (HIV discordant). Counselling messages are 
tailored around the couple’s HIV status. In both individual and couple HCT models, testing 
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can be client- or provider-initiated, opt-in or opt-out, and based in the clinic, home, 
workplace, or community.
Several reviews have explored the relationship between HCT and sexual behaviour in sub-
Saharan Africa [11–15]. They find that there is a strong and consistent increase in condom 
uptake among persons learning they are HIV-infected. This effect is even stronger in couple 
HCT, especially for HIV-discordant couples. However, the effect of HCT on sexual 
behaviour among HIV-uninfected persons who test alone is inconsistent.
Assessment of the impact of HCT on HIV acquisition is needed, as behaviours are imperfect 
proxies for HIV acquisition. Sexual behaviour is based on self-report, which can be biased 
from inaccurate recall and social desirability. Even accurate self-report may not perfectly 
predict HIV acquisition. Consistent condom use is associated with substantial reductions, 
but not elimination, of acquisition risk [16–20]. Similarly, questions about condom use or 
number of partners may mask certain behaviours, such as sero-sorting or selecting partners 
perceived to be less risky. Thus, direct estimates of the effect of HCT on HIV acquisition are 
necessary.
We conducted a systematic review to assess the impact of HCT on HIV acquisition among 
HIV-uninfected persons in sub-Saharan Africa. Specifically, we reviewed articles comparing 
A) sites that offered full HCT to sites that did not, B) persons who received HCT to persons 
who did not, and C) persons who received HCT individually to those who received HCT as a 
couple. We also assessed the quality of each article, including research design and analysis.
Methods
In this review, we sought to systematically identify all published articles from sub-Saharan 
Africa that assessed the impact of HCT on HIV acquisition. HCT was defined as a process 
that included pre-test counselling, HIV testing, and post-testing counselling, including return 
of test results. Persons who tested, but did not receive their results were classified as not 
having received HCT. Articles were included if they met the following search criteria:
1. Conducted in sub-Saharan Africa
2. Evaluated the impact of HCT among HIV-uninfected persons
3. Had a longitudinal study design
4. Had an HIV acquisition endpoint
5. Compared settings that provided HCT to settings that did not (Strata A), 
compared persons who were exposed to HCT to persons who were not (Strata 
B), or compared couple HCT to individual HCT (Strata C)
Further restrictions were not made based on the nature of HCT or on methodologic criteria, 
such as study design or analytic methods.
On August 9, 2013, PubMed and PsychINFO were searched using the following search 
terms: “HIV AND (acquisition OR incidence) AND testing AND counselling” to identify 
abstracts for review. Date of publication was not an inclusion criterion. A trained research 
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assistant screened all abstracts and identified those that potentially met review criteria. 
Ambiguous abstracts, such as those that reported HIV acquisition in only one sub-group, 
were included at this stage. These abstracts were then screened by an epidemiologist, and 
when necessary the full manuscripts were reviewed. Reference lists of included manuscripts 
were reviewed for additional articles that potentially met inclusion criteria. These additional 
articles were screened using the same procedures. Duplicates were removed.
Information on the study settings, populations, study designs, intervention and comparison, 
and HIV acquisition measures were abstracted. Setting attributes included country, year of 
data collection, and whether HCT was workplace, community, home, or clinic-based. 
Population characteristics included age, gender, and risk groups, such as general population 
or key populations (e.g. sex workers, men who have sex with men, or injection drug users).
Study designs were classified as randomised, pre/post, or exposed/unexposed cohorts. Pre/
post comparisons applied to persons who initially did not receive HCT and later did receive 
HCT. Exposed/unexposed comparisons compared persons who received HCT to those who 
did not receive HCT. Measures of HIV incidence were abstracted from articles as incidence 
rate ratios and/or hazard ratios and ninety five percent confidence intervals. Crude, adjusted, 
and inverse probability weighted effect measures were reported separately. When multiple 
sub-populations or types of analyses were included, each were reported separately. When 
available, sub-population effect measures were also reported. If the original authors had not 
calculated these measures, but sufficient information was available, we conducted these 
calculations using Open Epi (www.OpenEpi.com).
Information on study quality and bias was abstracted, as well. To assess the possibility of 
exposure misclassification, we assessed whether HCT status was ascertained via self-report 
or from clinical or study records. The number of times HCT status was ascertained was also 
assessed. To explore the possibility of confounding, we abstracted adjustment variables, 
including whether sexual risk behaviours were included. To assess the possibility of 
selection bias, the proportion of eligible persons that participated and the proportion of 
participants who were retained were abstracted. To determine the amount of information 
each study was contributing, the number of seroconversion events was abstracted.
Study characteristics were entered into a Microsoft Access database. Two trained research 
assistants reviewed each article independently. The two databases were compared for 
consistency by the epidemiologist, who adjudicated discrepancies. She re-read all articles to 
validate all information in the final database.
Meta-analysis was not conducted because the studies were heterogeneous in terms of 
populations, study designs, effect measures, and nature of HCT. Therefore, all assessments 
are descriptive. Our review procedures were not registered.
Results
The PubMed search yielded 1622 abstracts and the PsychINFO search yielded eight 
abstracts. Of these abstracts, 53 were identified as potentially eligible based on the abstracts 
and 12 were reviewed in their entirety. One was excluded as it reported on a duplicate 
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cohort, four were excluded for lacking a comparison population, incidence information, or 
both, and seven met all inclusion criteria. Five additional articles were identified for review 
from the reference lists. Of these, two were reviewed in their entirety. One was excluded for 
lacking a longitudinal design and one met all inclusion criteria. In total there were eight 
articles included in the review (Figure 1). Of these eight articles, one was in strata A, a 
comparison of sites with and without HCT [21], five were in strata B, comparisons of 
individuals who received HCT to those who did not [22–26], and two were in strata C, 
comparisons of individuals who received individual HCT to those who received couple HCT 
[27,28].
Settings and Populations
Six articles relied on data collected before the introduction of PEPFAR in 2003 [21, 22, 24–
26, 28], and two relied on data collected after this period [23, 27] (Table 1). Studies were 
conducted in Uganda [22, 24, 27], Rwanda [28], Zimbabwe [21, 25, 26], and South Africa 
[23]. Data were ascertained from five home-based settings [22–25, 27], two workplace 
settings [21, 26], and one clinical setting [28]. No studies were conducted exclusively among 
injecting drug users, sex workers, or men who have sex with men. All were conducted 
among the general population with most HIV acquisition risk presumed to be through 
heterosexual contact. The workplace-based studies were conducted predominantly among 
men [21, 26], the home-based studies were conducted among men and women [22–25, 27] 
and the clinical study was conducted among women attending antenatal or pediatric services 
[28]. One study was restricted to youth 15–24 years old [23], and the rest were conducted in 
a broader range of adult ages with minimum ages of 13–18 years and maximum ages of 35 
to >60 years. In all studies, HCT was conducted by trained counselors.
Strata A
The assessment in strata A was a two-arm cluster randomised controlled trial conducted in 
Zimbabwean workplaces from 2002–2004. In both intervention and control sites, 
participants received pre-test counselling at their own workplace. In the intervention sites, 
persons were also able to receive HIV test results and post-test counselling at their 
workplaces, whereas in the control sites, persons received a voucher to off-site nearby 
clinics, a less convenient approach. These different approaches led to different uptake of 
HIV test results and post-test counselling: 5% in the control sites and 71% in interventions 
sites, resulting in HCT-exposed and unexposed groups in the intention to treat analysis. 
There were modest differences in the mean HIV incidence in the intervention (1.37 per 100 
person years) and control sites (0.95 per 100 person years) for an intention to treat IRR of 
1.44 (95% CI: 0.77, 2.71). In the per protocol analysis, the IRR was closer to the null: 1.34 
(0.88, 2.06). Sixty-one seroconversion events were observed (Table 3). Approximately two 
thirds of eligible persons participated and, of these, approximately two thirds were retained.
Strata B
Five studies were included from strata B. Two of these studies were conducted in Zimbabwe 
(1993–1995 and 1998–2003), two in Uganda (1994-non-specified and 1999–2000), and one 
in South Africa (2006–2011) (Table 2). All were observational. Four were conducted in 
homes in enumerated population-based household surveys and one was conducted in a 
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workplace setting. One study had a pre/post design [26], three had exposed/unexposed 
designs [22, 24, 25], and one had both [23].
HIV incidence rates in the full populations ranged from 1.5 [22, 24] to 3.5 [26] per 100 
person years. In the full populations comparing those who received HCT to those who did 
not, IRRs ranged from 0.63 to 1.34 with all confidence intervals containing the null [22–26]. 
In analyses disaggregated by gender, IRRs among females ranged from 0.98 to 1.55 and 
IRRs among males ranged from 1.08 to 1.12; none were statistically significant. Only one 
assessment adjusted for sexual behaviour, and in this analysis HCT was found to be 
protective with a hazard ratio of 0.65 [23]. This study also used inverse probability weights 
to account for confounding and HCT was found to be protective with a hazard ratio of 0.59. 
In one study in which IRRs were disaggregated based on number of partners, there was a 
non-significant trend towards HCT being protective among those with more than one partner 
(IRR: 0.50) but not among those with only one partner (IRR: 1.16) [22].
All studies had methodologic limitations. None of these studies were randomised. Three did 
not account for confounding [24–26], one accounted for confounding in sub-analyses only 
[22], and one accounted for confounding in the main analysis [23]. Participation rates were 
between 75% and 80% in the two studies that reported this figure [24, 25]. Retention rates 
were 60–85% in the three studies that reported this figure [24–26]. One retrospective study 
had sufficient information to include 54% of persons, with at least one baseline and follow-
up endpoint [23]. In three studies, HCT status was ascertained based on study or clinic 
records [22, 24, 26], and in two studies it was based on self-report [23, 25]. Studies had 
between 36 and 248 seroconversion events.
Strata C: Couple HCT versus individual HCT
Two studies were identified within Strata C. The first was conducted in Rwanda from 1988–
1990 among women presenting for antenatal and pediatric care at an urban hospital [28]. 
The second was conducted in Uganda from 2006–2008 as part of a home-based HCT 
programme [27]. From these two studies, four incidence rate ratios were abstracted. In 
Rwanda, one assessment compared HIV-uninfected women before couple HCT and after 
couple HCT (pre/post). A second compared HIV-uninfected women who received HCT 
alone to HIV-uninfected women who received HCT with a partner (unexposed/exposed). In 
both comparisons there was a trend toward cHCT being protective: pre-post IRR: 0.44 (95% 
CI: 0.14, 1.22); unexposed-exposed IRR: 0.53 (95% CI: 0.18, 1.32). In Uganda, HIV 
acquisition was compared between HIV-uninfected persons who tested individually to those 
who tested with a partner, with males and females analysed separately. Overall, testing with 
a partner was significantly protective: 0.31 (95% CI: 0.19, 0.48), with a stronger trend 
among females than males.
Combined these two studies had 135 seroconversion events. Incidence was 2.7 per 100 
person years among HIV-discordant couples in Rwanda. Incidence was 0.5 per 100 person 
years among HIV-negative persons in unknown-status couples in Uganda. Neither study was 
randomised and neither adjusted for sexual behaviour. In both studies the participation rate 
was not stated.
Rosenberg et al. Page 6
Sex Transm Infect. Author manuscript; available in PMC 2017 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
In spite of the rapid and substantial expansion of HCT in the sub-Saharan Africa, there are 
few assessments of the impact of HCT on HIV acquisition, and, to our knowledge, these few 
assessments have not been synthesised previously. Based on this small body of evidence, 
two key trends emerge. First, individual HCT does not consistently increase or decrease HIV 
acquisition risk. Second, couple HCT reduces HIV acquisition risk by approximately half 
compared to individual HCT. These findings must be interpreted cautiously and within a 
broader context, as this body of evidence is modest with imprecise estimates and 
possibilities of bias.
In all unadjusted analyses, when comparing those receiving HCT to those not receiving 
HCT, all results were close to the null and imprecise. These observations are consistent with 
comparable assessments in sub-Saharan Africa and other parts of the world. Project Accept, 
a large cluster randomised controlled trial in SSA and Asia, comparing areas of widespread 
community-based HCT to more limited clinic-based HCT, found no difference in HIV 
incidence at a community level [29]. In Western settings, among men who have sex with 
men, HCT has not been associated with decreased risk, especially among those who test 
repeatedly [30].
HIV-uninfected persons testing as a couple were less likely to acquire HIV than persons 
testing alone, a finding consistent with other evidence and models in the region. In an 
assessment in Uganda and Kenya, couples receiving couple HCT had substantially lower 
HIV incidence than historical controls [31]. Similarly, HIV-uninfected women in HIV-
discordant couples who tested with their partners had lower HIV acquisition than HIV-
uninfected women who tested alone, when assumptions were introduced about the 
proportion of HIV-uninfected women who were in HIV-discordant relationships [32]. These 
findings are consistent with a mathematical model suggesting that the scale-up of couple 
HCT could reduce HIV incidence in Zambia and Rwanda by 35–60% [33].
Our findings are also consistent with assessments of the behavioural impacts of HCT in sub-
Saharan Africa. Individual HCT is associated with modest behaviour change in some HIV-
uninfected populations, but not others [11]. However, couple HCT is consistently and 
strongly associated with uptake of consistent condom use, especially in HIV-discordant 
couples, with meta-analysed odds ratios in excess of 60 [12–14, 34, 35]. The greater 
effectiveness of couple HCT is likely due to the importance of dyadic interventions for 
sexual activity, which are dyadic behaviours [36–38]. Regardless of why, promoting couple 
HCT over individual HCT is a key policy implication. Although the World Health 
Organisation has endorsed couple HCT for the region, it remains the exception, not the 
norm. Several strategies, such as partner notification and community invitations have been 
effective for increasing couple HCT and could have important implications if brought to 
scale [39–41]. Such efforts would not only have benefits on reduced HIV incidence, but also 
on reaching global HIV targets, including the 90-90-90 goals, elimination of mother to child 
transmission [42–44]
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Assessing the impact of HCT on HIV acquisition is methodologically challenging. First, all 
assessments of HIV acquisition require large cohorts followed for long periods with low, 
non-differential loss to follow-up. These longitudinal studies are time-consuming and 
expensive. Second, the impact of HCT on HIV acquisition cannot be assessed in randomised 
settings; deliberate withholding of HCT is unethical due to the incontrovertible benefits for 
HIV-infected persons. As a result, observational designs are typically employed, but these 
are less rigorous, especially without controlling for confounders. A third challenge is that 
both the primary exposure (HCT) and the primary outcome (HIV acquisition) require an 
HIV test. Thus, it is necessary to have independent ascertainment methods for establishing 
HCT (the exposure) and acquisition (the outcome). In some studies, the exposure is based on 
self-report, making it subject to information bias. And in some assessments, persons refuse 
to provide blood for outcome ascertainment, introducing potential bias.
In light of these methodologic challenges, this body of literature is small and 
methodologically weak. Only 8 articles are included with fewer than 1000 sero-conversion 
events, providing a limited foundation for drawing conclusions. Furthermore, all studies 
have important limitations. The study in Strata A was randomised at the cluster level. 
However, participation and retention were moderate, with possibilities for selection bias. All 
assessments in Strata B and C were non-randomised, and most did not control for key 
confounders: sexual behaviour and pregnancy. In the study that did control for these factors, 
HCT had no effect on HIV acquisition in unadjusted analysis but was protective in adjusted 
analysis [23]. This difference suggests that those who received HCT were at higher risk for 
HIV than those who did not; HCT helped lower the risk of testers (a higher risk population) 
to a level similar to that of non-testers (a lower risk population). It is not clear whether 
similar effects would have been observed, had other strata B studies controlled for these 
variables.
Integrating new biomedical advances into HCT is an important direction for future HCT 
programming. Most of these studies were conducted in the 1990s and early 2000s, prior to 
the findings that medical male circumcision and pre-exposure prophylaxis can be effective at 
reducing HIV acquisition rates among HIV-uninfected persons [7–9, 45–48]. As such, HCT 
in these studies was focused on behavioural prevention messages. To enhance its 
effectiveness, HCT can be used as a platform for providing referrals for biomedical 
prevention.
HCT with simple behavioural messages, when offered to HIV-uninfected persons without 
their sexual partners, is insufficient to consistently and substantially prevent HIV 
acquisition. However, HCT, when offered to HIV-infected persons, is critical for treatment 
initiation and subsequent reductions in transmissibility. Considering the effects of HCT on 
both HIV-uninfected and HIV-infected persons, HCT scale-up must continue. However, to 
maximise the prevention impacts, a paradigm shift towards couple HCT is needed, along 
with improved linkages to biomedical prevention for those who are HIV-uninfected and at 
high risk of HIV acquisition.
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Message Box
• In spite of intensive scale-up of HIV counselling and testing (HCT) in sub-
Saharan Africa, few well-designed studies have assessed the prevention 
impacts of HCT.
• Individual HCT is neither consistently protective nor harmful.
• Couple HCT is more protective than individual HCT.
• Interventions beyond HCT are needed for substantial declines in HIV 
acquisition, including couple HCT.
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Figure 1. Article Inclusion and Exclusion
Figure 1 displays articles identified, screened, eligible, and included.
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